Wolfe Research raised the price target for the Abbott Laboratories (NYSE:ABT) stock to ‘an Underperform’. The rating was released on June 06, 2023, according to finviz. The research report from UBS has reiterated the stock to Buy, with a price target set at $142. The stock was reiterated by Raymond James, who disclosed in a research note on January 27, 2023, to Outperform and set the price objective to $143. In their research brief published January 27, 2023, Morgan Stanley analysts reiterated the Abbott Laboratories stock to Overweight with a price target of $151.
What are the chances of Abbott Laboratories (ABT) Stock turning the corner?
